INDICATION(S)
The TC regimen ( Table 1) has been studied as adjuvant therapy in ovarian cancer [1] [2] [3] [4] [5] [6] [7] [8] and primary treatment of relapsed platinum-sensitive ovarian cancer. 9 Current guidelines recommend TC as primary adjuvant therapy for all stages of ovarian cancer, as therapy for recurrent platinum-sensitive tumors, and as neo-adjuvant therapy for patients with bulky stage III/IV ovarian cancer who are poor surgical candidates. 10 
DRUG PREPARATION
Follow institutional policies for preparation of hazardous medications when preparing carboplatin and paclitaxel. A. Carboplatin 1. Use carboplatin injection 10 mg/mL, or powder for reconstitution.
2. Reconstitute the powder to a concentration of 10 mg/mL with sterile water for injection (SWFI), 5% dextrose in water (D5W), or 0.9% sodium chloride (NS). 3. Dilute with 100 to 1,000 mL of D5W or NS. 4 . Carboplatin is less stable in saline solutions, with up to 5% degradation within 24 hours. 11 
SUPPORTIVE CARE A. Acute and Delayed Emesis Prophylaxis:
The TC regimen is predicted to cause acute emesis in 30% to 90% of patients. [12] [13] [14] The studies reviewed reported vomiting (all grades) in 33% to 45%, 3,4,6,7,9 severe (grade 3 or 4) vomiting in 4%, 1 nausea or vomiting (all grades) in 59%, 8 and severe nausea or vomiting (grade 3 or 4) in 1% of patients. 5 Appropriate acute emesis prophylaxis includes a serotonin antagonist and a corticosteroid plus or minus a neurokinin antagonist in selected patients. [12] [13] [14] One of the following regimens is suggested: The antiemetic therapy should continue for at least 2 days. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (greater than 24 hours) use of these agents, making a steroid or a steroid and dopamine antagonist combination most appropriate for follow-up therapy. 15 One of the following regimens is suggested: 17, 18 Routine prophylactic premedications should be given prior to paclitaxel 
Cycle repeats every 21 days
Variations: 1. Paclitaxel 175 mg/m 2 IV and carboplatin AUC 7 IV, both on day 1, cycle repeats every 21 days. 5 2. Paclitaxel 185 mg/m2 IV and carboplatin AUC 6 IV, both on day 1, cycle repeats every 21 days. 7 administration. The following regimen is suggested 19 : 1. Ranitidine 50 mg 2. Dexamethasone 10 or 20 mg 3. Diphenhydramine 50 mg All given IV over 30 minutes prior to paclitaxel. D. Hematopoietic Growth Factors: Accepted practice guidelines and pharmaco economic analysis suggest that antineoplastic regimens have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSFs) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended. 20, 21 In the trials reviewed, severe (grade 3 or 4) neutropenia was reported in 37% to 88% of patients, 1,2,4-7,9 severe (grade 3 or 4) granulocytopenia was reported in 58% to 70% of patients, 3, 8 and febrile neutropenia was reported in 4% to 8% of patients. 3, 6, 7, 9 Prophylactic use of CSFs is not recommended with this regimen. CSFs should be considered if a patient experiences febrile neutropenia or grade 4 neutropenia in a prior cycle of TC.
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute Common Terminology Criteria for Adverse Events (http://evs. nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but they make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Cardiovascular: Coagulation (all grades) 2%, 2 (grade 3 or 4) 1%, 2 edema (all grades) 18% to 22%, 4 4 (grade 3 or 4) 0.4% to 1% 2,5 ; total bilirubin (all grades) 12%, 6 (grade 3 or 4) 4%. 6 I. Hypersensitivity: (all grades) 9% to 35%, [2] [3] [4] 7, 9 (grade 3 or 4) 1% to 4%. 2,4,5,7 J. Infection/Fever: Fever (all grades) 13% to 14% 6,8 ; infection (all grades) 20% to 47%, 4,7,9 (grade 3 or 4) 3% to 36% 5,7,9 ; infection/fever (all grades) 9%. 2 4. Platelet count: a. Greater than or equal to 100,000 cells/ mcL. 2,4-8 b. Greater than 150,000 cells/mcL. 3 
Serum creatinine:
a. Less than or equal to 2 mg/dL. 2 b. Less than the upper limit of normal (ULN). 3 c. Less than 1.25 times ULN. 4, 7 d. Less than 1.5 times ULN. 6 e. Less than or equal to 120 micromole/L. 8 6. Creatinine clearance: a. Greater than or equal to 50 mL/min. 6 b. Greater than or equal to 60 mL/min. 8 
Serum bilirubin:
a. Less than 1.5 times ULN. 2, 6 b. Less than 1.25 times ULN. 4, 7 c. Less than or equal to 25 micromole/L. 8 8. AST/ALT: Less than or equal to 2.5 times ULN. 6 In clinical practice, a pretreatment ANC of 1,000 cells/mcL and platelets of 75,000 cells/ mcL are usually considered acceptable.
DOSAGE MODIFICATIONS A. Renal Function
1. Carboplatin -Carboplatin doses are commonly calculated using an equation based on the method of Calvert et al. 22 Calvert's group showed that the carboplatin dose in milligrams can be calculated using a desired area under the time versus concentration curve (AUC) and the patient's glomerular fi ltration rate (GFR 3 or 25% reduction of both paclitaxel and carboplatin. 5 6. Severe hypersensitivity reactions, stop paclitaxel. 5 7. Severe cardiac toxicity (symptomatic ventricular arrhythmias or more than 1st degree heart block), stop paclitaxel. 5 
